Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib versus adalimumab for moderate-to-severe hidradenitis suppurativa
IRCT20251112067973N5Phase 3Not yet recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hidradenitis suppurativa (HS) comparing Baricitinib with Adalimumab (2 arms). Primary endpoint: HiSCR50 at Month 3. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
baricitinibadalimumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on IRCT20251112067973N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251112067973N5.